SAN ANTONIO, Dec. 13 /PRNewswire/ -- The 29th Annual San Antonio Breast Cancer Symposium (SABCS) will be held December 13th-17th. This much- anticipated event began as a 1-day meeting with 141 attendees in 1978, and last year was attended by over 7600 participants from 86 countries. The San Antonio Breast Cancer Symposium is a collaborative effort of the Cancer Therapy and Research Center and the University of Texas Health Science Center at San Antonio.
Just as the number of attendees has grown over the years, so too has the number of opportunities available for clinicians to learn about the latest information in breast cancer research -- there has been a 20% increase in the number of posters and oral presentations since last year. Richard Santen will present this year's McGuire Lecture on the past and future of aromatase inhibitors. Three world-renowned physician researchers will present this year's plenary lectures, providing definitive updates in the rapidly- developing areas of breast cancer epigenetics, therapeutic approaches based on DNA repair deficits, and treatment options for sentinel node micrometastases. Four mini-symposia will pull together panels of experts to discuss tumor cell microenvironment, inflammation, angiogenesis, and breast cancer prevention. Poster sessions will feature 7 to 10 poster presentations, with in-depth discussions in specific subject areas including aromatase inhibitors, stem cells, HER2 and its family, mammography and imaging, and nuclear receptors.
The 2006 Brinker Award recipient for basic science is Evan Simpson, PhD, Director of the Prince Henry's Institute of Medical Research in Melbourne, Australia. Professor Simpson is recognized as the world leader in the field of estrogen biosynthesis. His research on the local production of estrogen in breast, brain, and bone in post-menopausal women has profoundly influenced the development of new drugs for the treatment of breast tumors.
The 2006 Brinker Award recipient for clinical research is George W. Sledge, Jr, MD, the Ballve-Lantero Professor of Oncology at the Indiana University Cancer Center in Indianapolis, Indiana. Dr. Sledge was one of the first to recognize the importance of local invasion and angiogenesis in breast cancer, and has been a leader in the application of anti-angiogenesis therapies. Recently, he has focused on novel biological therapies for breast cancer, and led the first-ever trial of an anti-VEGF monoclonal antibody for the treatment of metastatic breast cancer.
The objective of the SABCS is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.
San Antonio Breast Cancer Symposium
CONTACT: Marybeth Libonate of M2 Comm., +1-201-433-9400, for San AntonioBreast Cancer Symposium
Web site: http://www.sabcs.org/
